select a format

Single User License
USD 250 INR 16023
Site License
USD 500 INR 32045
Corporate User License
USD 750 INR 48068

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Mitsubishi Tanabe Pharma Corp (4508)-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Mitsubishi Tanabe Pharma Corp (4508)-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH31436D
  • |
  • Pages: 116
  • |
  • May 2017
  • |
  • |
  Request for Sample Report

Executive Summary

Summary

Mitsubishi Tanabe Pharma Corp (Mitsubishi Tanabe), a subsidiary of Mitsubishi Chemical Holdings Corp, is a pharmaceutical company. The company identifies, develops, manufactures, procures and commercializes ethical drugs and over-the-counter (OTC) pharmaceutical products. The company develops ethical drugs for autoimmune disease, diabetes and kidney diseases, central nervous system (CNS) diseases and others, and it also develops vaccines. The company major products include remicade, simponi, tenelia, ceredist and lexapro. Mitsubishi Tanabe major products include flucort f, nanpao, alegysal bien and okinazole. The company markets its products to wholesalers, hospitals, clinics, and drugstores. It also offers fine chemicals, information services, real-estate leasing and advertising, among others. The company along with its subsidiaries operates in Asia, Europe and North America. Mitsubishi Tanabe is headquartered in Chuo-ku, Osaka, Japan.

Mitsubishi Tanabe Pharma Corp (4508)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 7

Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 8

Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 9

Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 10

Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 11

Mitsubishi Tanabe Pharma Corp, Medical Devices Deals, 2011 to YTD 2017 13

Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 14

Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deal Details 21

Venture Financing 21

Forge Therapeutics Raises USD15 million in Series A Financing 21

Rigontec Raises Additional USD16.7 Million in Series A Financing 22

miRagen Therapeutics Raises USD41 Million in Series C Financing 23

Thrasos Therapeutics Raises USD21 Million in Series D Financing 24

Covagen Raises US$50.3 Million In Series B Financing 26

F-Star Alpha Raises US$13 Million In Series A Financing 28

Thrasos Therapeutics Raises US$35 Million In Venture Financing 29

Genocea Biosciences Raises US$30 Million In Series C Financing 31

GenKyoTex Raises US$26 Million In Extended Series C Financing 33

Syndexa Pharma Secures Additional Financing In Series B1 Round 35

GenKyoTex Secures US$21 Million In Series C Financing 36

f-star Secures US$21.7 Million In Financing Round 37

Genocea Biosciences Secures US$35 Million In Series B Venture Financing 38

Partnerships 40

Mitsubishi Tanabe Pharma Enters into Co-Promotion Agreement with Janssen Pharma for Stelara 40

Takeda Pharma and Shionogi Enter into Research Agreement with Sumitomo Dainippon Pharma, Ono Pharma and Mitsubishi Tanabe Pharma 41

Mitsubishi Tanabe Pharma Enters into Research Agreement with Medicine for Malaria Venture 43

Teikoku Seiyaku Enters into Agreement with Mitsubishi Tanabe Pharma 44

Sun Pharma Enters into Distribution Agreement with Mitsubishi Tanabe Pharma 44

Mitsubishi Tanabe Pharma Enters into Distribution Agreement with Janssen Biotech 45

Akebia Therapeutics Enters into Agreement with Mitsubishi Tanabe Pharma 46

Medicago Enters into Contract with Public Health Agency of Canada 47

Regeneron Pharma Enters into Agreement with Mitsubishi Tanabe Pharma 47

Cardiome Pharma Enters into Agreement with Mitsubishi Tanabe Pharma Europe 48

Mitsubishi Tanabe Enters into Co-Promotion Agreement with Johnson & Johnson K.K. 49

AstraZeneca Enters into Research Agreement with Mitsubishi Tanabe 50

AnGes MG Enters Into Co-Marketing Agreement With Mitsubishi Tanabe Pharma For Collategene 51

Medicago Enters Into Co-Development Agreement With A Global Pharma Company 52

Synageva BioPharma Extends Co-Development Agreement With Mitsubishi Tanabe Pharma 53

Mitsubishi Tanabe Pharma Expands its Co-Marketing Agreement with Daiichi Sankyo for MP-513 And TA-7284 54

Medicago Enters Into Co-Development Agreement With Mitsubishi Tanabe Pharma For Vaccines 55

Medicago Enters Into Co-Development Agreement With Cellectis 56

X-BODY Enters Into Research Agreement With Tanabe Research Labs 56

Synageva BioPharma Enters Into Research Agreement With Mitsubishi Tanabe Pharma 57

Medicago Enters Into Research Collaboration With USAMRIID 58

Mitsubishi Tanabe Pharma Enters Into Co-Development Agreement With Kyoto University 59

Merger 60

Bensis To Merge With Japanese Red Cross Plasma Fractionation Center 60

Licensing Agreements 60

Mitsubishi Tanabe Pharma Enters into Licensing Agreement with Kolon Life Science 60

Menarini Enters into Licensing Agreement with Mitsubishi Tanabe Pharma for Spedra 61

Tanabe Research Labs Enters into a Licensing Agreement with MedImmune 62

AnGes Enters into Licensing Agreement with Mitsubishi Tanabe Pharma 63

Neurocrine Biosciences Enters into Licensing Agreement with Mitsubishi Tanabe Pharma 64

Covagen Expands Licensing Agreement With Mitsubishi Tanabe Pharma And Tanabe Research Labs 65

BioInvent Extends Licensing Agreement With Mitsubishi Tanabe Pharma For Therapeutic Antibodies 66

Immune Design And Medicago Enter Into Licensing Agreement To Develop Influenza Vaccines 67

Dezima Pharma Enters Into Licensing Agreement With Mitsubishi Tanabe Pharma For DEZ-001 68

Covagen Enters Into Licensing Agreement With Mitsubishi Tanabe Pharma And Tanabe Research Labs 69

Medicago Enters Into Licensing Agreement With Philip Morris Products For Influenza Vaccines 71

Philip Morris Products Enters Into Licensing Agreement With Medicago For Protein Development Technologies 72

OncoEthix Enters Into Licensing Agreement With Mitsubishi Tanabe Pharma For OTX015 72

Nuron Biotech Enters Into Licensing Agreement With Mitsubishi Tanabe For HibTITER 73

Mitsubishi Tanabe Pharma Enters Into Licensing Agreement With Toray For TRK-820 74

Handok Pharma Enters Into Licensing Agreement With Mitsubishi Tanabe pharma 75

Equity Offering 76

miRagen Therapeutics Raises USD40.7 Million in Private Placement of Shares 76

Medicago Announces Private Placement Of Common Stock For US$3.4 Million 77

Medicago Completes Second Tranche Of Private Placement Of Shares For US$11 Million 78

Medicago Completes Private Placement Of Common Stock For US$24.5 Million 79

Medicago Completes Public Offering Of Units For US$17.72 Million 80

Asset Transactions 82

Sawai Pharma to Acquire Kashima Plant from Mitsubishi Tanabe Pharma Factory for USD39.3 Million 82

Acquisition 83

Nipro to Acquire Tanabe Seiyaku Hanbai from Mitsubishi Tanabe Pharma 83

CMIC Holdings Acquires Pharma Company from Mitsubishi Tanabe Pharma for USD32.2 Million 84

Medicago Completes Divestment Of 53.9% Stake To Mitsubishi Tanabe Pharma For US$ 172 Million In Going Private Transaction 85

Opko Health Completes Acquisition Of Cytochroma For Up To US$290 Million 87

Mitsubishi Tanabe To Acquire Remaining 49% Stake In Bipha From Nipro 89

Shire Completes Acquisition of Ferrokin Biosciences For Up To US$320 Million 90

Mitsubishi Tanabe Pharma Corp-Key Competitors 93

Key Employees 94

Locations And Subsidiaries 95

Head Office 95

Other Locations & Subsidiaries 95

Recent Developments 99

Strategy And Business Planning 99

Apr 01, 2016: MT Pharma Singapore Starts Business Operations Mitsubishi Tanabe Pharma's Subsidiary in Singapore 99

Feb 23, 2016: Mitsubishi Tanabe Pharma Enhances Operations in the United States 100

Financial Announcements 101

May 10, 2017: Mitsubishi Tanabe Pharma Reports Revenue Of JPY424 Billion In Fiscal 2017 101

Aug 02, 2016: Mitsubishi Tanabe Pharma Announces Financial Results for the First Three Months of the Fiscal year ending March 31, 2017 102

Feb 03, 2016: Mitsubishi Tanabe Pharma Reports Net Sales Of JPY340.9 Billion For The Nine Months Ended December 31, 2015 104

Government and Public Interest 105

Jun 06, 2016: Mitsubishi Tanabe Pharma contribute funding to Global Health Innovative Technology Fund 105

Jun 06, 2016: GHIT Fund Welcomes Ten New Partnerships With FUJIFILM, Otsuka, GSK, Johnson & Johnson, Kyowa Hakko Kirin, Merck, Mitsubishi Tanabe, Nipro, Sumitomo Dainippon Pharma and Salesforce.com 106

Product Approvals 108

Aug 30, 2016: FDA Accepts Mitsubishi Tanabe Pharma's NDA Filing for Edaravone to Treat ALS 108

Jun 20, 2016: Mitsubishi Tanabe Pharma Submits New Drug Application for Edaravone to Treat ALS in the United States 109

Clinical Trials 110

Jun 01, 2016: Minerva Neurosciences to Present data on MIN-117 110

May 26, 2016: Minerva Neurosciences Announces Positive Results in Phase IIA Trial of MIN-117 in Major Depressive Disorder 111

Apr 20, 2016: Mitsubishi Tanabe Pharma Presents Edaravone Clinical Trial Data in ALS at 2016 American Academy of Neurology Annual Meeting 112

Feb 22, 2016: Minerva Neurosciences Announces Completion of Patient Enrollment in Phase IIa Trial of MIN-117 in Major Depressive Disorder 113

Other Significant Developments 114

Apr 17, 2017: Notice regarding overseas subsidiary MT Pharma Strengthening business development in the ASEAN region 114

Apr 17, 2017: Notice regarding overseas subsidiary MT Pharma (Thailand) Strengthening business development in the ASEAN region 115

Appendix 116

Methodology 116

About GlobalData 116

Contact Us 116

Disclaimer 116

List of Figures

Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 8

Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 9

Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 10

Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 11

Mitsubishi Tanabe Pharma Corp, Medical Devices Deals, 2011 to YTD 2017 13

List of Tables

Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Key Facts, 2016 1

Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 8

Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 9

Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 10

Mitsubishi Tanabe Pharma Corp, Deals By Therapy Area, 2011 to YTD 2017 11

Mitsubishi Tanabe Pharma Corp, Medical Devices Deals, 2011 to YTD 2017 13

Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 14

Forge Therapeutics Raises USD15 million in Series A Financing 21

Rigontec Raises Additional USD16.7 Million in Series A Financing 22

miRagen Therapeutics Raises USD41 Million in Series C Financing 23

Thrasos Therapeutics Raises USD21 Million in Series D Financing 24

Covagen Raises US$50.3 Million In Series B Financing 26

F-Star Alpha Raises US$13 Million In Series A Financing 28

Thrasos Therapeutics Raises US$35 Million In Venture Financing 29

Genocea Biosciences Raises US$30 Million In Series C Financing 31

GenKyoTex Raises US$26 Million In Extended Series C Financing 33

Syndexa Pharma Secures Additional Financing In Series B1 Round 35

GenKyoTex Secures US$21 Million In Series C Financing 36

f-star Secures US$21.7 Million In Financing Round 37

Genocea Biosciences Secures US$35 Million In Series B Venture Financing 38

Mitsubishi Tanabe Pharma Enters into Co-Promotion Agreement with Janssen Pharma for Stelara 40

Takeda Pharma and Shionogi Enter into Research Agreement with Sumitomo Dainippon Pharma, Ono Pharma and Mitsubishi Tanabe Pharma 41

Mitsubishi Tanabe Pharma Enters into Research Agreement with Medicine for Malaria Venture 43

Teikoku Seiyaku Enters into Agreement with Mitsubishi Tanabe Pharma 44

Sun Pharma Enters into Distribution Agreement with Mitsubishi Tanabe Pharma 44

Mitsubishi Tanabe Pharma Enters into Distribution Agreement with Janssen Biotech 45

Akebia Therapeutics Enters into Agreement with Mitsubishi Tanabe Pharma 46

Medicago Enters into Contract with Public Health Agency of Canada 47

Regeneron Pharma Enters into Agreement with Mitsubishi Tanabe Pharma 47

Cardiome Pharma Enters into Agreement with Mitsubishi Tanabe Pharma Europe 48

Mitsubishi Tanabe Enters into Co-Promotion Agreement with Johnson & Johnson K.K. 49

AstraZeneca Enters into Research Agreement with Mitsubishi Tanabe 50

AnGes MG Enters Into Co-Marketing Agreement With Mitsubishi Tanabe Pharma For Collategene 51

Medicago Enters Into Co-Development Agreement With A Global Pharma Company 52

Synageva BioPharma Extends Co-Development Agreement With Mitsubishi Tanabe Pharma 53

Mitsubishi Tanabe Pharma Expands its Co-Marketing Agreement with Daiichi Sankyo for MP-513 And TA-7284 54

Medicago Enters Into Co-Development Agreement With Mitsubishi Tanabe Pharma For Vaccines 55

Medicago Enters Into Co-Development Agreement With Cellectis 56

X-BODY Enters Into Research Agreement With Tanabe Research Labs 56

Synageva BioPharma Enters Into Research Agreement With Mitsubishi Tanabe Pharma 57

Medicago Enters Into Research Collaboration With USAMRIID 58

Mitsubishi Tanabe Pharma Enters Into Co-Development Agreement With Kyoto University 59

Bensis To Merge With Japanese Red Cross Plasma Fractionation Center 60

Mitsubishi Tanabe Pharma Enters into Licensing Agreement with Kolon Life Science 60

Menarini Enters into Licensing Agreement with Mitsubishi Tanabe Pharma for Spedra 61

Tanabe Research Labs Enters into a Licensing Agreement with MedImmune 62

AnGes Enters into Licensing Agreement with Mitsubishi Tanabe Pharma 63

Neurocrine Biosciences Enters into Licensing Agreement with Mitsubishi Tanabe Pharma 64

Covagen Expands Licensing Agreement With Mitsubishi Tanabe Pharma And Tanabe Research Labs 65

BioInvent Extends Licensing Agreement With Mitsubishi Tanabe Pharma For Therapeutic Antibodies 66

Immune Design And Medicago Enter Into Licensing Agreement To Develop Influenza Vaccines 67

Dezima Pharma Enters Into Licensing Agreement With Mitsubishi Tanabe Pharma For DEZ-001 68

Covagen Enters Into Licensing Agreement With Mitsubishi Tanabe Pharma And Tanabe Research Labs 69

Medicago Enters Into Licensing Agreement With Philip Morris Products For Influenza Vaccines 71

Philip Morris Products Enters Into Licensing Agreement With Medicago For Protein Development Technologies 72

OncoEthix Enters Into Licensing Agreement With Mitsubishi Tanabe Pharma For OTX015 72

Nuron Biotech Enters Into Licensing Agreement With Mitsubishi Tanabe For HibTITER 73

Mitsubishi Tanabe Pharma Enters Into Licensing Agreement With Toray For TRK-820 74

Handok Pharma Enters Into Licensing Agreement With Mitsubishi Tanabe pharma 75

miRagen Therapeutics Raises USD40.7 Million in Private Placement of Shares 76

Medicago Announces Private Placement Of Common Stock For US$3.4 Million 77

Medicago Completes Second Tranche Of Private Placement Of Shares For US$11 Million 78

Medicago Completes Private Placement Of Common Stock For US$24.5 Million 79

Medicago Completes Public Offering Of Units For US$17.72 Million 80

Sawai Pharma to Acquire Kashima Plant from Mitsubishi Tanabe Pharma Factory for USD39.3 Million 82

Nipro to Acquire Tanabe Seiyaku Hanbai from Mitsubishi Tanabe Pharma 83

CMIC Holdings Acquires Pharma Company from Mitsubishi Tanabe Pharma for USD32.2 Million 84

Medicago Completes Divestment Of 53.9% Stake To Mitsubishi Tanabe Pharma For US$ 172 Million In Going Private Transaction 85

Opko Health Completes Acquisition Of Cytochroma For Up To US$290 Million 87

Mitsubishi Tanabe To Acquire Remaining 49% Stake In Bipha From Nipro 89

Shire Completes Acquisition of Ferrokin Biosciences For Up To US$320 Million 90

Mitsubishi Tanabe Pharma Corp, Key Competitors 93

Mitsubishi Tanabe Pharma Corp, Key Employees 94

Mitsubishi Tanabe Pharma Corp, Other Locations 95

Mitsubishi Tanabe Pharma Corp, Subsidiaries 95

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Mitsubishi Tanabe Pharma Corp, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.


Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com